作者
Jordan E Axelrad, Ahmad Bazarbashi, James Zhou, Daniel Castañeda, Amandeep Gujral, Dylan Sperling, Jason Glass, Manasi Agrawal, Simon Hong, Garrett Lawlor, David Hudesman, Shannon Chang, Shailja Shah, Vijay Yajnik, Ashwin Ananthakrishnan, Hamed Khalili, Jean-Frederic Colombel, Steven Itzkowitz, New York Crohn’s, Colitis Organization
发表日期
2020/4/1
期刊
Clinical Gastroenterology and Hepatology
卷号
18
期号
4
页码范围
872-880. e1
出版商
WB Saunders
简介
Background & Aims
Exposure to hormone contraception has been associated with an increased risk of relapse of inflammatory bowel diseases (IBDs). Little is known about the effects of cancer therapies, specifically hormone therapies, on the course of IBD.
Methods
We conducted a retrospective cohort study, collecting data from 5 medical centers, on patients with IBD who received a subsequent diagnosis of breast or prostate cancer from 1997 through 2018. For patients with quiescent IBD at their cancer diagnosis, the primary outcome was relapse of IBD. For patients with active IBD at their cancer diagnosis, the primary outcome was IBD remission.
Results
Our analysis included 447 patients with IBD (44% with Crohn’s disease, 53% with ulcerative colitis, and 3% with IBD unclassified) who had either breast (78%) or prostate (22%) cancer. At their cancer diagnosis, 400 patients (90%) had inactive IBD, and 47 (10 …
学术搜索中的文章
JE Axelrad, A Bazarbashi, J Zhou, D Castañeda… - Clinical Gastroenterology and Hepatology, 2020